Severity
Moderate
FDA Drug recall · Reported April 24, 2013
Chemical contamination: emission of strong odor after package was opened.
Pfizer Inc. recalled Levoxyl (levothyroxine sodium) tablets, USP 75 mcg, packaged in a) 100-count bottles (ND… - a moderate-severity action.
Levoxyl (levothyroxine sodium) tablets, USP 75 mcg, packaged in a) 100-count bottles (ND… was recalled by Pfizer Inc. in April 24, 2013. Reason: Chemical contamination: emission of strong odor after package was opened.. Check the official notice for the remedy. Verify recall #D-253-2013 with the FDA Drug before acting.
The recall
Pfizer Inc. issued this moderate-severity FDA Drug recall-Chemical contamination: emission of strong odor after package was opened..
Sourced from official FDA Drug enforcement records. Verify recall #D-253-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-253-2013) was formally reported on April 24, 2013, with the manufacturer initiating the action on March 28, 2013. It is classified under Moderate severity (Class II), with a current status of Completed. Pfizer Inc. is listed as the recalling firm, operating out of New York, NY. Federal records list the affected scope as 37809 bottles.
The documented reason for this recall is: Chemical contamination: emission of strong odor after package was opened. Distribution data in the federal record shows the product reached: Nationwide and PR. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
37809 bottles
Related Recalls
6
5 from same agency
Levoxyl (levothyroxine sodium) tablets, USP 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.
Chemical contamination: emission of strong odor after package was opened.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Completed |
| Recall number | D-253-2013 |
| Date reported | April 24, 2013 |
| Date initiated | March 28, 2013 |
| Recalling firm | Pfizer Inc. |
| Firm location | New York, NY |
| Affected scope | 37809 bottles |
| Distribution | Nationwide and PR |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 24, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.